An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence

Richard B. Rothman, David A. Gorelick, Stephen J. Heishman, Phil R. Eichmiller, Beada H. Hill, Jennifer Norbeck, Joseph G. Liberto

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Abstract

Several lines of evidence, including the well-established observation that κ opiate agonists produce dysphoria and psychotomimetic effects in humans, suggest that dysfunction of the endogenous κ opioid system may contribute to opioid and cocaine addiction. The objective of this open-label study was to determine the effectiveness of a functional κ antagonist as a treatment for opioid dependence. This was accomplished by combining a partial μ agonist/κ antagonist (buprenorphine, 4 mg, sublingual) with a μ antagonist (naltrexone, 50 mg by mouth), theoretically leaving κ antagonism as the major medication effect. Subjects were treatment-seeking heroin-dependent (as per Diagnostic and Statistical Manual of Mental Disorders, 4th ed.) men (41 ± 7 years old; 19 ± 8 years heroin use) eligible for methadone maintenance. After inpatient detoxification and a naloxone-challenge test to verify that they were not physically dependent on opioids, subjects received naltrexone. Starting on the fourth day, patients also received liquid buprenorphine. All patients received medication at the clinic 6 days per week and a full program of psychosocial treatment. The major endpoints of the study were: pupil diameter to determine if the μ agonist effects of buprenorphine were blocked by naltrexone, urine toxicology, and retention in treatment. Five patients (33%) completed the 3-month study. Four were abstinent from opioids and cocaine for the entire study, and one was abstinent from opioids and cocaine for the last 9 weeks. Six subjects dropped out due to either minor side effects or disliking the sensation of sublingual buprenorphine. There were no significant changes in pupillary diameter. The positive response to treatment exceeds that expected from naltrexone alone (90% dropout). These promising results suggest that controlled studies of this medication combination should be conducted. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)277-281
Number of pages5
JournalJournal of Substance Abuse Treatment
Volume18
Issue number3
DOIs
StatePublished - Apr 2000
Externally publishedYes

Keywords

  • Buprenorphine
  • Naltrexone
  • Opioid dependence
  • Opioid receptors

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • General Neuroscience

Fingerprint

Dive into the research topics of 'An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence'. Together they form a unique fingerprint.

Cite this